ATAI Fundamental Analysis - ATAI BECKLEY NV

Name: ATAI BECKLEY NV (ATAI) Stock
Brand: ATAI BECKLEY NV
Rating: 5 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ATAI. ATAI was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ATAI as it has an excellent financial health rating, but there are worries on the profitability. ATAI is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ATAI has reported negative net income.

In the past year ATAI has reported a negative cash flow from operations.

ATAI had negative earnings in each of the past 5 years.

ATAI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ATAI has a worse Return On Assets (-78.89%) than 71.20% of its industry peers.

The Return On Equity of ATAI (-103.85%) is worse than 61.26% of its industry peers.

		Industry Rank	Sector Rank
ROA	-78.89%
ROE	-103.85%
ROIC	N/A

ROA(3y)-52.42%

ROA(5y)-70.02%

ROE(3y)-67.79%

ROE(5y)-86.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATAI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ATAI does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ATAI has more shares outstanding

Compared to 5 years ago, ATAI has more shares outstanding

ATAI has a worse debt/assets ratio than last year.

2.2 Solvency

ATAI has an Altman-Z score of 6.65. This indicates that ATAI is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 6.65, ATAI belongs to the best of the industry, outperforming 80.63% of the companies in the same industry.

There is no outstanding debt for ATAI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	6.65

ROIC/WACCN/A

WACC7.54%

2.3 Liquidity

ATAI has a Current Ratio of 4.02. This indicates that ATAI is financially healthy and has no problem in meeting its short term obligations.

With a decent Current ratio value of 4.02, ATAI is doing good in the industry, outperforming 62.83% of the companies in the same industry.

A Quick Ratio of 4.02 indicates that ATAI has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 4.02, ATAI is in the better half of the industry, outperforming 64.40% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.02
Quick Ratio	4.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ATAI have decreased strongly by -72.50% in the last year.

ATAI shows a decrease in Revenue. In the last year, the revenue decreased by -1.91%.

The Revenue for ATAI have been decreasing by -75.28% on average. This is quite bad

EPS 1Y (TTM)-72.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%61.11%

Revenue 1Y (TTM)-1.91%

Revenue growth 3Y-75.28%

Revenue growth 5YN/A

Sales Q2Q%163.37%

3.2 Future

ATAI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.19% yearly.

ATAI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 236.62% yearly.

EPS Next Y45.22%

EPS Next 2Y23.88%

EPS Next 3Y13.75%

EPS Next 5Y14.19%

Revenue Next Year355.42%

Revenue Next 2Y-36.68%

Revenue Next 3Y18.97%

Revenue Next 5Y236.62%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATAI. In the last year negative earnings were reported.

Also next year ATAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ATAI's earnings are expected to grow with 13.75% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y23.88%

EPS Next 3Y13.75%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ATAI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ATAI BECKLEY NV

NASDAQ:ATAI (11/13/2025, 4:10:10 PM)

After market: 4.13 0 (0%)

4.13

-0.2 (-4.62%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-11 2025-11-11/bmo

Earnings (Next)03-16 2026-03-16/amc

Inst Owners13.93%

Inst Owner Change10.74%

Ins Owners2.66%

Ins Owner Change88.24%

Market Cap974.56M

Revenue(TTM)308.00K

Net Income(TTM)-149.27M

Analysts83.53

Price Target12.35 (199.03%)

Short Float %7.44%

Short Ratio2.57

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-0.25%

Min EPS beat(2)-17.64%

Max EPS beat(2)17.15%

EPS beat(4)1

Avg EPS beat(4)-15.72%

Min EPS beat(4)-62.27%

Max EPS beat(4)17.15%

EPS beat(8)4

Avg EPS beat(8)10%

EPS beat(12)7

Avg EPS beat(12)5.89%

EPS beat(16)9

Avg EPS beat(16)-5.32%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)7.31%

PT rev (3m)10.1%

EPS NQ rev (1m)-5.73%

EPS NQ rev (3m)-11.73%

EPS NY rev (1m)-2.33%

EPS NY rev (3m)-5.16%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)3.54%

Revenue NY rev (3m)59.84%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3164.14
P/FCF	N/A
P/OCF	N/A
P/B	6.78
P/tB	6.95
EV/EBITDA	N/A

EPS(TTM)-0.69

EYN/A

EPS(NY)-0.43

Fwd EYN/A

FCF(TTM)-0.35

FCFYN/A

OCF(TTM)-0.32

OCFYN/A

SpS0

BVpS0.61

TBVpS0.59

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-78.89%
ROE	-103.85%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-52.42%

ROA(5y)-70.02%

ROE(3y)-67.79%

ROE(5y)-86.99%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	830.23%
Cap/Sales	2024.35%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.02
Quick Ratio	4.02
Altman-Z	6.65

F-Score2

WACC7.54%

ROIC/WACCN/A

Cap/Depr(3y)268.35%

Cap/Depr(5y)673.01%

Cap/Sales(3y)220.74%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-72.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%61.11%

EPS Next Y45.22%

EPS Next 2Y23.88%

EPS Next 3Y13.75%

EPS Next 5Y14.19%

Revenue 1Y (TTM)-1.91%

Revenue growth 3Y-75.28%

Revenue growth 5YN/A

Sales Q2Q%163.37%

Revenue Next Year355.42%

Revenue Next 2Y-36.68%

Revenue Next 3Y18.97%

Revenue Next 5Y236.62%

EBIT growth 1Y18.39%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year0.75%

EBIT Next 3Y-16.28%

EBIT Next 5Y-3.12%

FCF growth 1Y21.04%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y26.11%

OCF growth 3YN/A

OCF growth 5YN/A

ATAI BECKLEY NV / ATAI FAQ

What is the fundamental rating for ATAI stock?

ChartMill assigns a fundamental rating of 3 / 10 to ATAI.

What is the valuation status for ATAI stock?

ChartMill assigns a valuation rating of 0 / 10 to ATAI BECKLEY NV (ATAI). This can be considered as Overvalued.

What is the profitability of ATAI stock?

ATAI BECKLEY NV (ATAI) has a profitability rating of 0 / 10.

Can you provide the financial health for ATAI stock?

The financial health rating of ATAI BECKLEY NV (ATAI) is 7 / 10.

ATAI BECKLEY NV (ATAI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ATAI BECKLEY NV / ATAI FAQ

What is the fundamental rating for ATAI stock?

What is the valuation status for ATAI stock?

What is the profitability of ATAI stock?

Can you provide the financial health for ATAI stock?